First true initial ictal SPECT in partial epilepsy verified by electroencephalography
Authors Pastor J, Domínguez-Gadea L, Sola RG, Hernando V, Meilán ML, De Dios E, Martínez-Chacó JL, Martínez M
Published 8 February 2008 Volume 2008:4(1) Pages 305—309
Jesús Pastor1, Luis Domínguez-Gadea2, Rafael G Sola3, Virgilio Hernando3, María Luisa Meilán4, Eva De Dios4, José Luis Martínez-Chacón4, Marcos Martínez5
1Clinical Neurophysiology; 2Nuclear Medicine; 3Neurosurgery; 4Anaesthesiology and Reanimation; Hospital Universitario “La Princesa”, Madrid, Spain; 5Anaesthesiology and Reanimation, Cardiovascular Unit of Adults, Hospital Ramón y Cajal, Madrid, Spain
Abstract: Drug-resistant epilepsy can sometimes be treated by surgery. In these cases, an accurate identification of the epileptogenic area must be addressed before resection. Ictal SPECT is one of the presurgical evaluations that can be performed, but usually, the increase in the regional cerebral perfusion observed is produced by diffusion of ictal activity. Here we describe a patient studied with v-EEG and foramen ovale electrodes that suffered a seizure after intravenous infusion of etomidate. The sequence of etomidate administration, followed by radiotracer and seizure was good enough for us to suspect that a true initial ictal SPECT was observed. We have implemented a kinetic model with four compartments, previously described (Andersen 1989), in order to estimate the fraction of hydrophilic radiotracer in the brain during the pre-ictal and ictal periods. This model has shown that the fraction of hydrophilic radiotracer during the seizure into the brain would be between 18.9% and 42.3% of total infused. We show the first true initial ictal SPECT demonstrated by bioelectrical recordings of the brain activity, obtained by a correct succession of events and compatible with theoretical data obtained from the kinetic model.
Keywords: etomidate, foramen ovale electrodes, mathematical model, temporal lobe epilepsy
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF]